New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - interferon alpha-2c 30 miu/ml - eye drops, solution - 1500000iu/0.05ml - active: interferon alpha-2c 30 miu/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - interferon alfa-2b 30 miu;   - powder for injection - 30 miu - active: interferon alfa-2b 30 miu   excipient: albumin dibasic sodium phosphate glycine monobasic sodium phosphate dihydrate water for injection benzyl alcohol water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 9 miu/ml - solution for injection - 9 miu/ml - active: interferon alfa-2a 9 miu/ml excipient: albumin ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 25 miu/ml - solution for injection - 30 miu - active: interferon alfa-2b 25 miu/ml excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - intron a redipen is used in the treatment of: · hairy cell leukaemia in splenectomised or non-splenectomised patients; · chronic myelogenous leukaemia;

United States - English - NLM (National Library of Medicine)

genentech, inc. - peginterferon alfa-2a (unii: q46947fe7k) (peginterferon alfa-2a - unii:q46947fe7k) - peginterferon alfa-2a 180 ug in 1 ml - adult patients: pegasys, as part of a combination regimen with other hepatitis c virus (hcv) antiviral drugs, is indicated for the treatment of adults with chc and compensated liver disease. for information about the safe and effective use of other hcv antiviral drugs to be used in combination with pegasys, refer to their prescribing information. pegasys monotherapy is only indicated for the treatment of patients with chc and compensated liver disease if there are contraindications or significant intolerance to other hcv antiviral drugs. pediatric patients: pegasys in combination with ribavirin is indicated for the treatment of pediatric patients 5 years of age and older with chc and compensated liver disease. limitations of use : - pegasys alone or in combination with ribavirin without additional hcv antiviral drugs is not recommended for treatment of patients with chc who previously failed therapy with an interferon-alfa. - pegasys is not recommended for treatment of patients with chc who have had solid

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 30 miu/ml (final fill volume = 0.72 ml, includes a 20% fill overage) - solution for injection - 18 miu/0.6ml - active: interferon alfa-2a 30 miu/ml (final fill volume = 0.72 ml, includes a 20% fill overage) excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 15 miu/ml - solution for injection - 18 miu - active: interferon alfa-2b 15 miu/ml excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - intron a redipen is used in the treatment of: · hairy cell leukaemia in splenectomised or non-splenectomised patients; · chronic myelogenous leukaemia;

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 50 miu/ml - solution for injection - 60 miu - active: interferon alfa-2b 50 miu/ml excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - intron a redipen is used in the treatment of: · hairy cell leukaemia in splenectomised or non-splenectomised patients; · chronic myelogenous leukaemia;

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 30 miu/ml (final fill volume, 0.72 ml, includes a 20 % fill overage); ribavirin 200mg;   - combination - 18 miu/0.6 ml, 200 mg - active: interferon alfa-2a 30 miu/ml (final fill volume, 0.72 ml, includes a 20 % fill overage) excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection active: ribavirin 200mg   excipient: ethylcellulose as aqueous dispersion (solids) hypromellose as component of opadry 03a14309 pink iron oxide red as component of opadry 03a14309 pink iron oxide yellow as component of opadry 03a14309 pink magnesium stearate maize starch microcrystalline cellulose purified talc as component of opadry 03a14309 pink sodium starch glycolate starch titanium dioxide as component of opadry 03a14309 pink triacetin

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - peginterferon alfa-2b (unii: g8rgg88b68) (peginterferon alfa-2b - unii:g8rgg88b68) - peginterferon alfa-2b 40 ug in 0.1 ml - sylatron™ is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. sylatron is contraindicated in patients with: - a history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b - autoimmune hepatitis - hepatic decompensation (child-pugh score >6 [class b and c]) risk summary based on findings from animal studies, sylatron can cause embryo-fetal harm when administered to a pregnant woman. available human data with sylatron use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. administration of nonpegylated interferon alfa-2b was abortifacient in rhesus monkeys at doses approximately 13 times higher than the recommended dose of 6 mcg/kg/week (see data ). in the u.s. general population, the estimated background risk of major birth defects and miscarriage is 2-4% and